APOC2 (Apolipoprotein C-II) is a component of triglyceride-rich lipoproteins that serves as an essential cofactor for lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing triglycerides in circulating lipoproteins. While primarily studied in peripheral lipid metabolism, emerging evidence links APOC2 to brain lipid homeostasis and neurodegenerative diseases.
| APOC2 Protein |
|---|
| Protein Name | Apolipoprotein C-II |
| Gene | APOC2 |
| UniProt ID | P02735 |
| PDB Structures | 1lev, 1sh4 |
| Molecular Weight | 8.8 kDa |
| Subcellular Localization | Secreted, plasma lipoprotein particles |
| Protein Family | Apolipoprotein C family |
¶ Domain Architecture
APOC2 is a small 79-amino acidapolipoprotein that lacks a signal peptide but is secreted via an unconventional pathway. The protein adopts an amphipathic alpha-helical structure that allows it to associate with lipoprotein particles. The C-terminal region contains the lipoprotein lipase-binding domain.
- Lipoprotein Lipase Cofactor: APOC2 is essential for LPL activity, enabling hydrolysis of triglyceride-rich lipoproteins (VLDL, chylomicrons)
- Triglyceride Clearance: Regulates plasma triglyceride levels through LPL-mediated lipolysis
- Lipoprotein Remodeling: Participates in VLDL and chylomicron remodeling
- Detected in cerebrospinal fluid and brain tissue
- May regulate lipid transport in the central nervous system
- Potential role in neuronal lipid homeostasis
- Expressed by astrocytes and neurons
- APOC2 levels altered in AD brain and CSF
- May influence amyloid-beta metabolism through lipid transport
- Lipid dysregulation is a feature of AD pathogenesis
- Genetic variants may modify AD risk
- Altered lipid metabolism in PD substantia nigra
- APOC2 may affect alpha-synuclein-lipid interactions
- Potential role in membrane integrity of dopaminergic neurons
- Dysregulated lipid metabolism contributes to neurodegeneration
- APOC2 may have protective roles in neuronal lipid homeostasis
¶ Stroke and Vascular Dementia
- APOC2 affects triglyceride-rich lipoprotein metabolism
- Vascular contributions to neurodegenerative diseases
- No direct APOC2-targeted therapies for neurodegeneration
- Statins and other lipid-lowering agents may indirectly affect APOC2
- LPL modulators under investigation
- Recombinant APOC2 for functional studies
- Transgenic mouse models with APOC2 alterations
- Wang & Hegele, APOC2 genetics (2003)
- Jong et al., APOC2 function (1999)
- Tremblay et al., Lipoprotein lipase (2004)
- Mahley & Rall, Apolipoproteins in CNS (2000)